Lymphir (Denileukin Diftitox-Cxdl) for Lymphoma

Overview
Lymphir is a biologic treatment approved by the U.S. Food and Drug Administration (FDA) for adults with relapsed or refractory stage 1 through stage 3 cutaneous T-cell lymphoma who have already received at least one prior systemic therapy. Individuals must have a serum albumin level of at least 3 grams per deciliter to start treatment. Lymphir is also known by its drug name, denileukin diftitox-cxdl.

Lymphir combines two components: interleukin-2 (IL-2) and diphtheria toxin. The IL-2 allows Lymphir to bind specifically to cancer cells, while the diphtheria toxin is responsible for killing those cells. Additionally, Lymphir targets regulatory T-cells, which can sometimes shield cancer cells. By eliminating these protective cells, Lymphir enhances the immune system’s ability to fight the cancer.

How do I take it?
Prescribing information states that Lymphir is administered as an intravenous infusion. The recommended dosage is based on actual body weight. It is given on Days 1 through 5 of a 21-day treatment cycle. Individuals may need to take premedications as recommended by their health care provider. It is important for this medication to be administered exactly as prescribed.

Side effects
Common side effects of Lymphir include increased transaminases (liver enzymes), decreased albumin levels, nausea, edema (swelling), decreased hemoglobin, fatigue, musculoskeletal pain, rash, chills, constipation, pyrexia (fever), and capillary leak syndrome (a condition where fluid leaks from small blood vessels into surrounding tissues, causing swelling and low blood pressure).

Rare but serious side effects may include life-threatening or fatal capillary leak syndrome, visual impairment, infusion-related reactions, and hepatotoxicity (liver damage). Individuals taking this drug should be closely monitored for these conditions, and treatment may need to be withheld or discontinued if they occur.

For more information about this treatment, visit:

Lymphir — Drugs.com

Lymphir (Denileukin Diftitox-Cxdl) for Injection, for Intravenous Use — U.S. Food and Drug Administration